Top Massachusetts Biotech Startups (210)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Conagen is an accomplished biotechnology company located in the greater Boston biotech corridor. We innovate and develop synthetic biology solutions for supporting global partners across a spectrum of current and developing markets. From our proprietary strain development to fermentation and process scale-up, Conagen impacts partners’ abilities to sell and market products in the food, nutrition, flavor and fragrance, pharmaceutical, and...
REGENHU is a provider of 3D Bioprinters, and has developed, manufactured and distributed innovative hardware and software tools for 3D Bioprinting applications since 2007. We are a pioneer in the field and our global customer portfolio comprises leading universities as well as key players in the biotech industry, pharma, cosmetics, and MedTech. We are rapidly expanding our world class team of...
We’re on a mission to unlock molecular machines by understanding and respecting their complexities. We’ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines. We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in...
At Ark, we are transforming bioprocessing by championing a model-first approach that combines biology, chemistry, and physics with the predictive power of machine learning and AI. By replacing traditional trial-and-error methods with hybrid models, we empower organizations to predict outcomes, optimize processes, and scale with precision—dramatically reducing R&D timelines, cutting costs, and increasing accessibility to life-saving therapies and innovative products....
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock...
FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only...
Beaconcure supports biopharmaceutical companies and CROs with Verify, a secure online workspace for AI-enabled clinical study analysis validation. Designed in partnership with trusted large pharmaceutical companies and used in an increasing number of approved products, Verify streamlines validation workflows, reduces error rates, and increases efficiency compared to traditional processes. Beaconcure is revolutionizing the way new drugs and vaccines are approved for...
Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients.
Genialis is a computational precision medicines company unravelling complex biology to find new ways to address disease. ResponderID™, Genialis’ clinical biomarker discovery platform, defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development. Genialis is trusted by biopharma and big pharma alike, and together, we bring precision to medicine.
Anodyne Nanotech, Inc. is a preclinical-stage biotech company developing differentiated, transdermal forms of high-value drugs. The company’s macroporous microneedle technology provides the first practical and cost-effective platform, Hero Patch, to deliver clinically meaningful doses of macromolecules such as monoclonal antibodies or small molecules (such as ibuprofen) for fast and sustained delivery. We pride ourselves on providing a painless experience for...
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and...
Allonnia is a bio-ingenuity company™ dedicated to extracting value where others see waste. We believe that elegant solutions to the world’s biggest problems will be found in the world’s smallest organisms. So, we’re pioneering novel approaches and imaginative combinations in biotechnology and engineering to solve waste challenges in nature, using nature. We are focused on three key sectors of mining, industry,...
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information,...
We are Nested Therapeutics, a biotech company inspired by service and driven by a desire to make a meaningful impact. We are creative innovators who challenge our own assumptions as we strive to find new, overlooked areas of opportunity to design therapeutics for a perfect fit. We embrace diverse perspectives and experiences in a space for everyone to add value...
Fortis partners with diagnostics and life sciences companies to design, validate, and manufacture solutions to solve their complex development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across the world including four R&D sites...
We are Voyager Therapeutics, a pre-clinical stage biotech compelled by curiosity and powered by persistence. Voyagers are bold innovators who are energized in unlocking the full potential of AAV gene therapy employing our TRACER™ capsid discovery platform. Our resolve is to advance the field of AAV gene therapy, and through our innovative capsids, we are extending the reach and impact...
Matterworks is developing advanced AI-powered software and proprietary chemistry reagents to enable real-time, quantitative metabolomics to accelerate the research, development, and manufacturing of biologic therapeutics. Metabolomics measures all the small molecules a cell needs to function. In spite of its far-reaching potential impact across life science disciplines, adoption of metabolomics remains limited and lags behind other ‘omic techniques due to a...
